Kilitch Drugs (India) Limited KILITCH NSEPHARMA
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 19.2% over 5 years.
- Profit CAGR of 42.4% over 5 years.
CONS
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KILITCH Kilitch Drugs (India) Limited NSEPHARMA | 182.39 | 20.45 | ₹637.66 Cr | - | 13.15% | 12.36% | 19.25% | 42.40% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | - | 56.17 Cr | 61.23 Cr | 43.14 Cr | 48.92 Cr | 53.81 Cr | 89.60 Cr |
| Cost of Revenue | - | 32.76 Cr | 28.70 Cr | 25.46 Cr | 26.36 Cr | 30.89 Cr | 44.15 Cr |
| Gross Profit | - | 23.41 Cr | 32.53 Cr | 17.68 Cr | 22.56 Cr | 22.92 Cr | 45.45 Cr |
| Operating Expenses | - | 15.48 Cr | 18.78 Cr | 15.26 Cr | 18.38 Cr | 17.71 Cr | 24.29 Cr |
| Operating Income | - | 7.93 Cr | 13.75 Cr | 2.42 Cr | 4.18 Cr | 5.21 Cr | 21.16 Cr |
| EBITDA | - | 10.46 Cr | 16.29 Cr | 5.82 Cr | 11.70 Cr | 7.68 Cr | 22.64 Cr |
| Interest Expense | - | 1.40 Cr | 1.60 Cr | 1.53 Cr | 1.44 Cr | 1.15 Cr | 1.44 Cr |
| Pretax Income | - | 8.25 Cr | 13.84 Cr | 3.45 Cr | 9.40 Cr | 5.60 Cr | 20.21 Cr |
| Tax Provision | - | 2.64 Cr | 3.63 Cr | 1.19 Cr | 1.36 Cr | 1.28 Cr | 5.33 Cr |
| Net Income | - | 5.96 Cr | 10.40 Cr | 3.03 Cr | 8.19 Cr | 4.43 Cr | 14.52 Cr |
| Diluted EPS | 2.68 | 1.85 | 6.47 | 0.92 | 2.48 | 1.25 | 4.24 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 138.86 Cr | 153.61 Cr | 198.32 Cr | 235.47 Cr |
| Cost of Revenue | - | 77.13 Cr | 80.47 Cr | 104.58 Cr | 126.13 Cr |
| Gross Profit | - | 61.72 Cr | 73.14 Cr | 93.74 Cr | 109.34 Cr |
| Operating Expenses | - | 47.37 Cr | 52.05 Cr | 65.38 Cr | 76.37 Cr |
| Operating Income | - | 14.35 Cr | 21.08 Cr | 28.35 Cr | 32.98 Cr |
| EBITDA | - | 20.48 Cr | 28.63 Cr | 42.63 Cr | 47.84 Cr |
| Interest Expense | - | 4.92 Cr | 5.93 Cr | 5.04 Cr | 5.56 Cr |
| Pretax Income | - | 12.01 Cr | 19.35 Cr | 34.47 Cr | 38.65 Cr |
| Tax Provision | - | 3.73 Cr | 5.78 Cr | 9.53 Cr | 9.15 Cr |
| Net Income | - | 10.45 Cr | 14.60 Cr | 26.70 Cr | 30.17 Cr |
| Diluted EPS | - | 3.28 | 4.49 | 16.60 | 8.91 |
Compounded Sales Growth
| 5 Years: | 19.25% |
| 1 Year: | 46.30% |
Compounded Profit Growth
| 5 Years: | 42.40% |
| 1 Year: | 26.50% |
Stock Price Performance
| 1 Year: | -14.95% |
| 6 Months: | -1.06% |
| 3 Months: | +16.23% |
| 1 Month: | +18.60% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 219.52 Cr | 240.06 Cr | 312.78 Cr | 457.75 Cr |
| Current Assets | - | 126.40 Cr | 145.99 Cr | 173.92 Cr | 222.20 Cr |
| Cash & Equivalents | - | 19.79 Cr | 18.91 Cr | 9.75 Cr | 15.77 Cr |
| Inventory | - | 2.41 Cr | 5.58 Cr | 21.58 Cr | 11.52 Cr |
| Receivables | - | 54.29 Cr | 63.22 Cr | 84.74 Cr | 120.18 Cr |
| Total Liabilities | - | 68.94 Cr | 64.39 Cr | 112.33 Cr | 180.88 Cr |
| Current Liabilities | - | 68.87 Cr | 64.22 Cr | 84.31 Cr | 121.60 Cr |
| Long Term Debt | - | - | 0 | 27.77 Cr | 58.60 Cr |
| Total Debt | - | 22.19 Cr | 31.65 Cr | 49.42 Cr | 88.71 Cr |
| Total Equity | - | 151.60 Cr | 176.29 Cr | 202.33 Cr | 279.65 Cr |
| Shares Outstanding | - | 3.18 Cr | 3.29 Cr | 3.29 Cr | 3.50 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.59 Cr | -1.53 Cr | 17.54 Cr | 23.96 Cr |
| Investing Cash Flow | - | 7.92 Cr | -8.16 Cr | -39.95 Cr | -100.44 Cr |
| Financing Cash Flow | - | -71.63 L | 8.81 Cr | 13.24 Cr | 82.45 Cr |
| Capital Expenditure | - | -3.81 Cr | -6.45 Cr | -46.87 Cr | -99.51 Cr |
| Free Cash Flow | - | -1.23 Cr | -7.99 Cr | -29.33 Cr | -75.55 Cr |
| Net Change in Cash | - | 9.78 Cr | -88.45 L | -9.16 Cr | 5.97 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 44.5% | 47.6% | 47.3% | 46.4% |
| Operating Margin % | - | 10.3% | 13.7% | 14.3% | 14.0% |
| Net Margin % | - | 7.5% | 9.5% | 13.5% | 12.8% |
| ROE % | - | 6.9% | 8.3% | 13.2% | 10.8% |
| ROCE % | - | 9.5% | 12.0% | 12.4% | 9.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for KILITCH